2024 PARTNERS
Expertise Partner - Sartorius
Sartorius is a leading global partner of the biopharmaceutical industry dedicated to enabling cell and gene therapy developers to manufacture and commercialize their advanced therapy medicinal products (ATMPs). Over the last decade the company has expanded its legacy portfolio of single-use bioprocessing solutions through the acquisition of complementary advanced therapy consumables, services, and technologies—from plasmid engineering and manufacturing to cell culture media, reagents and monolithic chromatography. Sartorius’ advanced therapy solutions are designed to overcome current production challenges by enhancing productivity, improving process economics, and supporting safe and regulatory compliant manufacturing. Sartorius products are currently used in approved cell and gene therapies and actively support clinical pipelines worldwide. The company’s continued investment in innovative solutions demonstrates their commitment to advancing the field and making access to these life-saving treatments a reality.
Innovation Partner - Agilent
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions.
Event Partner - Akron Bio
Akron Bio enables the advancement of cell and gene therapies through its portfolio of cytokines and media supplements, as well as its comprehensive suite of manufacturing services, including the production of plasmid DNA, precision gene editing tools, and specialized medias. Akron partners with advanced therapy developers, providing them with critical materials and services at the scale, level of compliance, and regulatory support necessary to drive novel treatments from discovery to commercialization, thereby addressing critical unmet needs in the patient community.
Event Partner - Akron Bio
Touchlight is a innovative CDMO providing DNA services including the manufacture of enzymatically produced dbDNA t (doggybone DNA) to enable the development of genetic medicines. Touchlight produces DNA as an API or critical starting material for use in advanced therapy manufacturing, including mRNA and DNA vaccines, viral vector production (AAV and Lentivirus), non-viral gene therapy, and genome editing. Our clients are supported from pre-clinical through development and supply.